MiniMed Group, Inc. (MMED) Income Statement
MMED FY2026 at a glance
Fiscal year ended April 30, 2026 · U.S. dollarsMMED revenue and net income
Where MMED's revenue goes
FY2026Each bar shows an amount and its share of revenue. MMED kept −10.7% of revenue as net income.
MMED profit margins
MMED growth rates
to FY2026| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +14.3% | +11.4% | — | — |
| Gross profit | +10.2% | +8.7% | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
MMED quarterly EPS vs estimates
MiniMed beat the analyst EPS estimate in 1 of the last 3 quarters.
MMED income statement
| FY2026 | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Revenue | $3.10B | $2.71B | $2.47B | $2.25B |
| Cost of revenue | $1.42B | $1.19B | $1.03B | $937.0M |
| Gross profit | $1.68B | $1.52B | $1.44B | $1.31B |
| Research & development | $448.0M | $438.0M | $437.0M | $429.0M |
| Sales, general & admin | $1.18B | $1.13B | $1.06B | $960.0M |
| Total operating expenses | $1.63B | $1.73B | $1.51B | $1.38B |
| Operating income | $49.0M | −$202.0M | −$69.0M | −$69.0M |
| Income before taxes | −$187.0M | −$203.0M | −$70.0M | −$76.0M |
| Income taxes | $128.0M | $48.0M | $38.0M | $16.0M |
| Net income | −$331.0M | −$250.0M | −$112.0M | −$96.0M |
| EBITDA | $205.0M | $107.0M | $59.0M | $39.0M |
| EPS (diluted) | −$0.52 | −$0.89 | — | — |
| Gross margin | 54.2% | 56.2% | 58.2% | 58.3% |
| Operating margin | 1.6% | −7.4% | −2.8% | −3.1% |
| Net margin | −10.7% | −9.2% | −4.5% | −4.3% |
| Jul '26 | Apr '26 | Jan '26 | Oct '25 | Jul '25 | Apr '25 | Jan '25 | |
|---|---|---|---|---|---|---|---|
| Revenue | $843.0M | $837.0M | $790.0M | $752.0M | $723.0M | $724.0M | $687.0M |
| Cost of revenue | $378.0M | $357.0M | $428.0M | $324.0M | $314.0M | $321.0M | $292.0M |
| Gross profit | $465.0M | $480.0M | $362.0M | $428.0M | $409.0M | $402.0M | $395.0M |
| Research & development | $115.0M | $99.0M | $114.0M | $111.0M | $125.0M | $109.0M | $112.0M |
| Sales, general & admin | $312.0M | $299.0M | $309.0M | $318.0M | $283.0M | $327.0M | $268.0M |
| Total operating expenses | $427.0M | $398.0M | $455.0M | $438.0M | $720.0M | $607.0M | $665.0M |
| Operating income | $38.0M | $82.0M | −$93.0M | −$10.0M | $3.0M | −$204.0M | $22.0M |
| Income before taxes | $4.0M | −$90.0M | −$99.0M | −$12.0M | −$13.0M | −$204.0M | $21.0M |
| Income taxes | $4.0M | $93.0M | $12.0M | $19.0M | — | $17.0M | — |
| Net income | $0 | −$183.0M | −$119.0M | −$27.0M | −$19.0M | −$209.0M | −$10.0M |
| EBITDA | $79.0M | $121.0M | −$60.0M | $29.0M | $42.0M | — | — |
| EPS (diluted) | $0.13 | −$0.60 | $0.08 | — | — | — | — |
| Gross margin | 55.2% | 57.3% | 45.8% | 56.9% | 56.6% | 55.5% | 57.5% |
| Operating margin | 4.5% | 9.8% | −11.8% | −1.3% | 0.4% | −28.2% | 3.2% |
| Net margin | 0.0% | −21.9% | −15.1% | −3.6% | −2.6% | −28.9% | −1.5% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in MMED's financial statements (latest annual report filed June 29, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
MMED financial results
In fiscal year 2026 (ended April 30, 2026), MiniMed reported revenue of $3.1 billion, up 14.3% from the year before. It had a net loss of $331.0 million, a net profit margin of −10.7%. Diluted earnings per share came to −$0.52.
See the MMED stock overview for the latest quote and news, or the MMED chart for price history and technical indicators.
MMED income statement FAQ
What is MiniMed's annual revenue?
MiniMed reported total revenue of $3.1 billion for fiscal year 2026, which ended on April 30, 2026. That was up 14.3% from $2.7 billion the previous year.
Is MiniMed profitable?
No. MiniMed reported a net loss of $331.0 million in fiscal 2026, a net profit margin of −10.7%; its operating margin was 1.6%.
What is MiniMed's gross margin?
MiniMed's gross margin was 54.2% in fiscal 2026: for every $100 of revenue, MiniMed kept $54 after the direct cost of its products and services.
How much does MiniMed spend on research and development?
MiniMed spent $448.0 million on research and development in fiscal 2026, 14.4% of revenue.
What are MiniMed's earnings per share?
MiniMed earned $-0.52 per diluted share in fiscal 2026, compared with $-0.89 a year earlier.
When does MiniMed's fiscal year end?
MiniMed's fiscal year ends in April. The latest annual report covers the year ended April 30, 2026 and was filed on June 29, 2026.